194 related articles for article (PubMed ID: 33721913)
1. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
[TBL] [Abstract][Full Text] [Related]
2. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
3. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
Liu Z; Chen Z; Wang J; Zhang M; Li Z; Wang S; Dong B; Zhang C; Gao J; Shen L
J Hematol Oncol; 2018 Aug; 11(1):109. PubMed ID: 30157900
[TBL] [Abstract][Full Text] [Related]
4. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation.
Du R; Xiao N; Han L; Guo K; Li K; Chen Z; Zhang H; Zhou Z; Huang Y; Zhao X; Bian H
Sci Rep; 2024 Apr; 14(1):9167. PubMed ID: 38649770
[TBL] [Abstract][Full Text] [Related]
8. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
[TBL] [Abstract][Full Text] [Related]
9. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
[TBL] [Abstract][Full Text] [Related]
10. Deoxypodophyllotoxin, a Lignan from
Kwak AW; Lee MH; Yoon G; Cho SS; Choi JS; Chae JI; Shim JH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961992
[TBL] [Abstract][Full Text] [Related]
11. Isoliquiritigenin Suppressed Esophageal Squamous Carcinoma Growth by Blocking EGFR Activation and Inducing Cell Cycle Arrest.
Ye L; Zhang J; Zhang Y; Gu B; Zhu H; Mao X
Biomed Res Int; 2020; 2020():9259852. PubMed ID: 32190688
[TBL] [Abstract][Full Text] [Related]
12. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
[TBL] [Abstract][Full Text] [Related]
13. Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.
Chen D; Hong R; Cao Y; Wu Q; Wang Y; Chen J; Li J; Zhang W; Zhan Q
Carcinogenesis; 2023 Aug; 44(6):451-462. PubMed ID: 37279554
[TBL] [Abstract][Full Text] [Related]
14. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.
Lv L; Wang SC; Mo JY; Huang KL; Xu ML; Liu J
Biochem Biophys Res Commun; 2022 Jan; 586():129-136. PubMed ID: 34839191
[TBL] [Abstract][Full Text] [Related]
15. Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma.
Wang J; Zhang Z; Che Y; Yuan Z; Lu Z; Li Y; Wan J; Sun H; Chen Z; Pu J; He J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):469-481. PubMed ID: 29308536
[TBL] [Abstract][Full Text] [Related]
16. Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy.
Han L; Xiang X; Fu Y; Wei S; Zhang C; Li L; Liu Y; Lv H; Shan B; Zhao L
Phytomedicine; 2024 Jun; 128():155539. PubMed ID: 38522311
[TBL] [Abstract][Full Text] [Related]
17. Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.
Meng RY; Jin H; Nguyen TV; Chai OH; Park BH; Kim SM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768915
[TBL] [Abstract][Full Text] [Related]
18. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
19. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
Guo XF; Li SS; Zhu XF; Dou QH; Liu D
Cancer Chemother Pharmacol; 2018 Sep; 82(3):383-394. PubMed ID: 29909520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
